VBI Vaccines Inc.

NASDAQ:VBIV  
1.76
-0.07 (-3.82%)
Products

VBI Vaccines Announces FDA Approval Of PreHevbrio For Prevention Of Hepatitis B

Published: 12/01/2021 12:42 GMT
VBI Vaccines Inc. (VBIV) - Vbi Vaccines Announces FDA Approval of Prehevbrio™ for the Prevention of Hepatitis B in Adults.
Vbi Vaccines Inc - Expects to Make Prehevbrio Available in U.S. in Q1 of 2022.